ClinicalTrials.gg
CompletedNCT01763996Updated Apr 13, 2016Results posted

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

A Phase 4 interventional study of Febuxostat and Febuxostat placebo in Coronary Artery Disease, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-04-13.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,105 studies in Coronary Artery Disease with a site in United States — 101 open to participants now, 146 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Enrollment
596th of 746
30 · median 107
Started
2013
with 59 others
Phase 4
141 of 1,105
10 open now
Registered
541st of 1,105
by date

Among the 1,105 studies in Coronary Artery Disease with a site in United States, this one is the 596th largest by enrollment of the 746 interventional ones that give a count, is one of 60 that started in 2013, is one of 141 in phase 4, and was the 541st registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

101 of the 1,105 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,105 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of febuxostat on coronary artery flow in patients with coronary artery disease.

Read the detailed description

The drug being tested in this study is called febuxostat. Febuxostat is being tested to treat people who have angina. This study will look at the heart and blood flow of people who take febuxostat.

The study will enroll approximately 30 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups (or sequences)-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Sequence 1: 6 weeks febuxostat followed by 6 weeks of placebo.
  • Sequence 2: 6 week placebo followed by 6 weeks of febuxostat

All participants will be asked to take one capsule at the same time each day throughout the study. All participants will be asked to record any time they have angina symptoms during the study.

This single-center trial will be conducted in the United States. The overall time to participate in this study is 16 weeks. Participants will make 7 visits to the clinic including a final visit 4 weeks after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a serum urate ≥4.0 mg/dL.
  4. Has a history of coronary artery disease, defined as:

    1. ≥50 % stenosis of ≥1 major coronary artery confirmed by angiography; OR
    2. Documented prior myocardial infarction (MI) by enzymes/ (ECG) changes; OR
    3. Documented prior exercise or pharmacologic stress/echo myocardial imaging study positive for ischemia.
  5. Has estimated (eGFR) ≥30 mL/min by Modification of Diet in Renal Disease (MDRD) at the screening visit.
  6. Has a change in coronary artery flow from rest to isometric handgrip exercise of less than + 10 mL/min.
  7. Is male or female and aged 18 to 85 years, inclusive.
  8. A female of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study.
  9. Is on stable (30 days prior to Screening Day-21) medication doses prescribed for any underlying medical condition (ie, hypertension, angina) and is expected to remain on stable doses throughout the study duration.
  10. Is able to take nitroglycerin for anginal symptoms during study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to Screening.
  2. Has received allopurinol or febuxostat in a previous clinical study or as a therapeutic agent with-in 6 months of randomization.
  3. Has gout or secondary hyperuricemia (eg, due to myeloproliferative disorder, or organ transplant) or has experienced a gout flare.
  4. Has a history of xanthinuria.
  5. Has known to magnetic resonance imaging (MRI) scanning
  6. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  7. Has a history of or allergies to febuxostat or nitroglycerin.
  8. Has \<10 g/L at Screening.
  9. Has a history or clinical manifestations of a significant medical condition that might affect his/her ability to complete the study.
  10. Has any of the following during Screening:

    1. Class III or IV heart failure.
    2. Acute coronary syndrome or a coronary revascularization procedure within 2 months of Screening.
    3. Wolff-Parkinson-White syndrome.
    4. Pacemaker or implantable cardioverter defibrillator.
    5. Arrhythmias (ie, supraventricular tachycardia (SVT), atrial fibrillation/flutter, or ventricular tachycardia (VT) during Screening).
  11. Has a recent history (within the last 2 months prior to Screening) of acute coronary syndrome or a coronary revascularization procedure, MI, heart failure, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  12. Has a contraindication for using nitrates (severe anemia, increased intracranial pressure, and those with a known sensitivity or hypersensitivity to nitroglycerin or its ingredients, or other nitrates or nitrites; concomitant use either regularly and/or intermittently, with phosphodiesterase type 5 (PDE5) inhibitors).
  13. Has unstable angina that:

    1. Occurs when the patient is at rest.
    2. Is prolonged, usually greater than 20 minutes.
    3. Occurs with increasing in intensity, duration, and/or frequency.
    4. Responds poorly to nitroglycerin (ie, does not go away after three doses of nitroglycerin or returns after the nitroglycerin helped at first).
  14. Is unable to exercise sufficiently to complete exercise treadmill test (ETT) due to leg claudication, arthritis, deconditioning, or associated pulmonary disease.
  15. Has severe or critical valvular disease documented by echocardiogram, or congenital heart disease.
  16. The subject has (LVEF) less than 35%, as documented by echocardiogram, left ventriculogram, or gated blood pool scan..
  17. The subject has cardiac conduction defects (ie, second- or third-degree atrioventricular block, or sick sinus syndrome) at Screening
  18. Has hypertrophic cardiomyopathy.
  19. Has an (ALT) or aspartate aminotransferase (AST) level of greater than 2.0 times the , has active liver disease, or jaundice.
  20. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the Screening Visit.
  21. Is required or expected to require excluded medications including digoxin or digoxin-containing compounds.
  22. If female, is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  23. Has participated in another clinical trial within the past 30 days.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Sequence 1: Febuxostat 80 mg + Placebo

    Febuxostat 80 mg, capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks in Period 2.

    Drug: Febuxostat · Drug: Febuxostat placebo

  • Experimental
    Sequence 2: Placebo + Febuxostat 80 mg

    Febuxostat placebo-matching capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks in Period 2.

    Drug: Febuxostat · Drug: Febuxostat placebo

Interventions

  • Febuxostat capsules

  • DrugFebuxostat placebo

    Febuxostat placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo

    Coronary artery flow was measured using magnetic resonance imaging (MRI) at rest and during sustained isometric (static) handgrip exercises. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

Secondary outcomes

  1. Change in Coronary Artery Cross-Sectional Area From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo

    Coronary artery cross-sectional area was measured by MRI at rest and during sustained isometric (static) handgrip exercise. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

  2. Change in Coronary Flow Velocity From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo

    Coronary flow velocity was measured by MRI at rest and during sustained isometric (static) handgrip exercise. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

  3. Change in Coronary Artery Flow Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo

    Coronary artery flow was measured by MRI before and following administration of nitroglycerin under the tongue. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

  4. Change in Coronary Artery Cross Sectional Area Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo

    Coronary artery cross sectional area was measured by MRI before and following administration of nitroglycerin under the tongue. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

  5. Change in Coronary Flow Velocity Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo

    Coronary flow velocity was measured by MRI before and following administration of nitroglycerin under the tongue. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

  6. Change in Time to Onset of ≥1 mm ST-Segment Depression During Exercise Treadmill Test (ETT)

    Time in seconds to ischemic ECG changes during ETT. Continuous electrocardiography (ECG) was performed during an exercise treadmill test (modified Bruce protocol) to assess the onset of ST-segment depression after administration of febuxostat or placebo for 6 weeks in participants with a normal ST segment at randomization. . Data at the end of each treatment period was combined for the febuxostat and the placebo arms.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

  7. Change in Maximum ST-segment Depression During Exercise Treadmill Test

    Continuous ECG was performed during an exercise treadmill test (modified Bruce protocol) to assess the maximum ST-segment depression after 6 weeks of febuxostat or placebo treatment in participants with a normal ST segment at randomization. A negative change from Baseline indicates improvement. Data at the end of each treatment period was combined for the febuxostat and the placebo arms.

    Time frame: Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)

  8. Percentage of Participants Stopping Exercise Treadmill Test Due to Angina at the End of the Administration of Febuxostat and Placebo

    An exercise treadmill test (modified Bruce protocol) was performed. Data at the end of each treatment period was combined for the febuxostat and the placebo arms.

    Time frame: At the end of each 6 week treatment period (Week 6 and Week 12)

  9. Time to Onset of Angina During Exercise Treadmill Test at the End of the Administration of Febuxostat and Placebo

    Time in seconds to ischemic chest pain/ angina during ETT. Data at the end of each period was combined for the febuxostat and the placebo arms

    Time frame: At the end of each 6 week treatment period (Week 6 and Week 12)

  10. Exercise Duration

    Exercise duration is the exercise time in seconds during ETT. Data at the end of each period was combined for the febuxostat and the placebo arms.

    Time frame: At the end of each 6 week treatment period (Week 6 and Week 12)

07

Results

Posted Apr 13, 2016

Participant flow

Participants took part in the study at one investigative site in the United States from 29 May 2013 (first participant signed the formed consent form) to 14 April 2015.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSequence 1: Febuxostat 80 mg + PlaceboSequence 2: Placebo + Febuxostat 80 mg
Started1515
Completed1515
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSequence 1: Febuxostat 80 mg + PlaceboSequence 2: Placebo + Febuxostat 80 mg
Started1515
Completed1514
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryChange in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo

Coronary artery flow was measured using magnetic resonance imaging (MRI) at rest and during sustained isometric (static) handgrip exercises. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Least squares mean · mL/min
Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo
mL/minPlaceboFebuxostat 80 mg
Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo8.8 (0.40 to 17.28)10.7 (2.23 to 19.11)
Statistical analysis
  • Placebo vs Febuxostat 80 mg · ANOVA · p = 0.756 (0.05 level of significance) · Ls mean difference: 1.8 · 95% CI -10.10 to 13.76Analysis of variance (ANOVA) model that includes sequence, period, and treatment as fixed factors and subjects within sequence as a random factor.
SecondaryChange in Coronary Artery Cross-Sectional Area From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo

Coronary artery cross-sectional area was measured by MRI at rest and during sustained isometric (static) handgrip exercise. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Least squares mean · mm^2
Change in Coronary Artery Cross-Sectional Area From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo
mm^2PlaceboFebuxostat 80 mg
Change in Coronary Artery Cross-Sectional Area From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo0.45 (-0.177 to 1.074)0.03 (-0.595 to 0.656)
SecondaryChange in Coronary Flow Velocity From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo

Coronary flow velocity was measured by MRI at rest and during sustained isometric (static) handgrip exercise. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Least squares mean · cm/second
Change in Coronary Flow Velocity From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo
cm/secondPlaceboFebuxostat 80 mg
Change in Coronary Flow Velocity From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo1.6 (-0.10 to 3.40)2.2 (0.43 to 3.93)
SecondaryChange in Coronary Artery Flow Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo

Coronary artery flow was measured by MRI before and following administration of nitroglycerin under the tongue. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Least squares mean · mL/min
Change in Coronary Artery Flow Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo
mL/minPlaceboFebuxostat 80 mg
Change in Coronary Artery Flow Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo17.0 (-6.00 to 39.98)13.0 (-2.53 to 28.43)
SecondaryChange in Coronary Artery Cross Sectional Area Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo

Coronary artery cross sectional area was measured by MRI before and following administration of nitroglycerin under the tongue. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Least squares mean · mm^2
Change in Coronary Artery Cross Sectional Area Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo
mm^2PlaceboFebuxostat 80 mg
Change in Coronary Artery Cross Sectional Area Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo3.35 (1.449 to 5.244)2.86 (1.582 to 4.138)
SecondaryChange in Coronary Flow Velocity Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo

Coronary flow velocity was measured by MRI before and following administration of nitroglycerin under the tongue. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Least squares mean · cm/second
Change in Coronary Flow Velocity Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo
cm/secondPlaceboFebuxostat 80 mg
Change in Coronary Flow Velocity Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo-0.95 (-4.120 to 2.213)-0.66 (-2.792 to 1.472)
SecondaryChange in Time to Onset of ≥1 mm ST-Segment Depression During Exercise Treadmill Test (ETT)

Time in seconds to ischemic ECG changes during ETT. Continuous electrocardiography (ECG) was performed during an exercise treadmill test (modified Bruce protocol) to assess the onset of ST-segment depression after administration of febuxostat or placebo for 6 weeks in participants with a normal ST segment at randomization. . Data at the end of each treatment period was combined for the febuxostat and the placebo arms.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Mean · seconds
Change in Time to Onset of ≥1 mm ST-Segment Depression During Exercise Treadmill Test (ETT)
secondsPlaceboFebuxostat 80 mg
Change in Time to Onset of ≥1 mm ST-Segment Depression During Exercise Treadmill Test (ETT)514 ± 252316 ± 122
SecondaryChange in Maximum ST-segment Depression During Exercise Treadmill Test

Continuous ECG was performed during an exercise treadmill test (modified Bruce protocol) to assess the maximum ST-segment depression after 6 weeks of febuxostat or placebo treatment in participants with a normal ST segment at randomization. A negative change from Baseline indicates improvement. Data at the end of each treatment period was combined for the febuxostat and the placebo arms.

Time frame:
Baseline and at the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Mean · mm
Change in Maximum ST-segment Depression During Exercise Treadmill Test
mmPlaceboFebuxostat 80 mg
Change in Maximum ST-segment Depression During Exercise Treadmill Test1.3 ± 0.51.5 ± 0.7
SecondaryPercentage of Participants Stopping Exercise Treadmill Test Due to Angina at the End of the Administration of Febuxostat and Placebo

An exercise treadmill test (modified Bruce protocol) was performed. Data at the end of each treatment period was combined for the febuxostat and the placebo arms.

Time frame:
At the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Stopping Exercise Treadmill Test Due to Angina at the End of the Administration of Febuxostat and Placebo
percentage of participantsPlaceboFebuxostat 80 mg
Percentage of Participants Stopping Exercise Treadmill Test Due to Angina at the End of the Administration of Febuxostat and Placebo0.03.6
SecondaryTime to Onset of Angina During Exercise Treadmill Test at the End of the Administration of Febuxostat and Placebo

Time in seconds to ischemic chest pain/ angina during ETT. Data at the end of each period was combined for the febuxostat and the placebo arms

Time frame:
At the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Mean · seconds
Time to Onset of Angina During Exercise Treadmill Test at the End of the Administration of Febuxostat and Placebo
secondsPlaceboFebuxostat 80 mg
Time to Onset of Angina During Exercise Treadmill Test at the End of the Administration of Febuxostat and Placebo—330 ± NA
SecondaryExercise Duration

Exercise duration is the exercise time in seconds during ETT. Data at the end of each period was combined for the febuxostat and the placebo arms.

Time frame:
At the end of each 6 week treatment period (Week 6 and Week 12)
Reported as:
Least squares mean · seconds
Exercise Duration
secondsPlaceboFebuxostat 80 mg
Exercise Duration702 (682.1 to 721.6)722 (700.5 to 742.9)

Adverse events

Collected over First dose of study drug to up to 30 days after the last dose of study drug (Up to 16 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/30 (0%)7/30 (23.3%)
Febuxostat 80 mg—0/30 (0%)6/30 (20%)
Most frequent other events
Most frequent other events
EventPlaceboFebuxostat 80 mg
Common coldInfections and infestations3/301/30
HeadacheNervous system disorders1/302/30
Musculoskeletal discomfortMusculoskeletal and connective tissue disorders1/302/30
Ventricular extrasystolesCardiac disorders1/302/30
Dermatitis contactSkin and subcutaneous tissue disorders2/300/30
FatigueGeneral disorders2/300/30

Baseline characteristics

All participants

Age, Continuous
Age, Continuous(years)All Participants
Mean59 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female3
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Participants
African-American5
White25
Region of Enrollment
Region of Enrollment(participants)All Participants
United States30
Height
Height(cm)All Participants
Mean176 ± 7.7
Weight
Weight(kg)All Participants
Mean87.8 ± 16
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)All Participants
Mean28.3 ± 4.12
Left Ventricular Ejection Fraction
Left Ventricular Ejection Fraction(percent)All Participants
Mean56.8 ± 9.24
08

Study locations

1 site
  • Baltimore, Maryland, United States
09

References and documents

Publications

  • Hays AG, Iantorno M, Schar M, Lai S, Czarny M, Breton E, Palmer RN, Whelton A, Weiss RG, Gerstenblith G. The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial. Am Heart J. 2018 Mar;197:85-93. doi: 10.1016/j.ahj.2017.11.006. Epub 2017 Nov 23. PubMed 29447788 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Mar 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2013
First posted
Jan 9, 2013
Start
May 2013
Primary completionActual
Mar 2015
CompletionActual
Apr 2015
Results first posted
Apr 13, 2016
Last update
Apr 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01763996
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
May 2013
Primary completion
Mar 2015
Completion
Apr 2015
Results posted
Apr 13, 2016
Last update
Apr 13, 2016

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion